David Guy Kirsch


Barbara Levine University Distinguished Professor

My clinical interests are the multi-modality care of patients with bone and soft tissue sarcomas and developing new sarcoma therapies. My laboratory interests include utilizing mouse models of cancer to study cancer and radiation biology in order to develop new cancer therapies in the pre-clinical setting.

Appointments and Affiliations

  • Barbara Levine University Distinguished Professor
  • Adjunct Professor in the Department of Radiation Oncology

Contact Information

  • Office Location: LSRC Building, Room B327, Durham, NC 27710
  • Office Phone: (919) 681-8586
  • Email Address: david.kirsch@duke.edu


  • Harvard Medical School, 2007
  • Harvard Medical School, 2006
  • Massachusetts General Hospital, 2005
  • Greater Baltimore Medical Center, 2001
  • Ph.D. Johns Hopkins University School of Medicine, 2000
  • M.D. Johns Hopkins University School of Medicine, 2000
  • B.S. Duke University, 1993

Courses Taught

  • PHARM 393: Research Independent Study
  • PHARM 394: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 495: Research Independent Study

In the News

Representative Publications

  • Floyd, W; Pierpoint, M; Su, C; Patel, R; Luo, L; Deland, K; Wisdom, AJ; Zhu, D; Ma, Y; DeWitt, SB; Williams, NT; Lazarides, AL; Somarelli, JA; Corcoran, DL; Eward, WC; Cardona, DM; Kirsch, DG, Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus., The Journal of Clinical Investigation, vol 133 no. 13 (2023) [10.1172/jci149310] [abs].
  • Wang, D; Harris, J; Kraybill, WG; Eisenberg, B; Kirsch, DG; Ettinger, DS; Kane, JM; Barry, PN; Naghavi, A; Freeman, CR; Chen, Y-L; Hitchcock, YJ; Bedi, M; Salerno, KE; Severin, D; Godette, KD; Larrier, NA; Curran, WJ; Torres-Saavedra, PA; Lucas, DR, Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials., Jama Oncol, vol 9 no. 5 (2023), pp. 646-655 [10.1001/jamaoncol.2023.0042] [abs].
  • Kuo, HC; Daniel, AR; Driver, LM; Lee, CL; Kirsch, DG, Histological assessment of intestinal injury by ionizing radiation (2023) [10.1016/bs.mcb.2023.03.001] [abs].
  • Bokhari, RS; Beheshti, A; Blutt, SE; Bowles, DE; Brenner, D; Britton, R; Bronk, L; Cao, X; Chatterjee, A; Clay, DE; Courtney, C; Fox, DT; Gaber, MW; Gerecht, S; Grabham, P; Grosshans, D; Guan, F; Jezuit, EA; Kirsch, DG; Liu, Z; Maletic-Savatic, M; Miller, KM; Montague, RA; Nagpal, P; Osenberg, S; Parkitny, L; Pierce, NA; Porada, C; Rosenberg, SM; Sargunas, P; Sharma, S; Spangler, J; Tavakol, DN; Thomas, D; Vunjak-Novakovic, G; Wang, C; Whitcomb, L; Young, DW; Donoviel, D, Looking on the horizon; potential and unique approaches to developing radiation countermeasures for deep space travel., Life Sci Space Res (Amst), vol 35 (2022), pp. 105-112 [10.1016/j.lssr.2022.08.003] [abs].